Truist lowered the firm’s price target on Maze Therapeutics (MAZE) to $64 from $68 and keeps a Buy rating on the shares. The firm has updated its outlook following the company’s 10-K filing, revising its operating expense assumptions and updating its share count to reflect outstanding pre-funded warrants, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Maze Therapeutics price target raised to $58 from $52 at JPMorgan
- Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
- Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
- Maze Therapeutics falls -29.8%